Search results
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Zacks via Yahoo Finance· 19 hours agoBristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it...
Zacks Research Comments on Bristol-Myers Squibb’s FY2024 Earnings (NYSE:BMY)
ETF DAILY NEWS· 2 days agoBristol-Myers Squibb (NYSE:BMY – Free Report) – Equities research analysts at Zacks Research issued their FY2024 earnings estimates for shares of Bristol-Myers Squibb in a report issued on Thursday ...
Is Bristol Myers' Dividend in Danger?
Motley Fool via Yahoo Finance· 5 days agoBristol Myers Squibb (NYSE: BMY) pays investors an attractive dividend, which yields an incredibly high rate of 5.5%. That's nearly four times the S&P...
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
The Wall Street Journal· 5 days agoBristol Myers Squibb said its trial evaluating a combination of cancer treatments failed to meet its...
UPDATE 3-US FDA approves expanded use of Bristol Myers' cancer cell therapy
Reuters via Yahoo Finance· 11 hours agoThe U.S. health regulator on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer called follicular ...
Bristol Myers Squibb reports setback in lung cancer trial By Investing.com
Investing.com· 5 days agoBristol Myers Squibb (NYSE: NYSE:BMY) disclosed that its Phase 3 CheckMate -73L trial for treating a...
KRAS inhibitors: The next frontier beckons
Pharmaceutical Technology via Yahoo Finance· 40 minutes agoAlthough KRAS and its links to cancer were discovered decades ago, the characteristics of its protein structure were thought to make it “undruggable”....
Big Pharma layoffs continue, as Bristol-Myers Squibb cuts 2,200 jobs, $1.5B in costs
BenefitsPRO· 6 days agoAt a time when drugmakers Eli Lilly & Co. and Novo Nordisk are scrambling to meet demand for their...
News Highlights: Top Company News of the Day - Friday at 7 PM ET
Morningstar· 5 days agoBristol Myers Squibb said its trial evaluating a combination of cancer treatments failed to meet its primary endpoint. The television company, which produces "The Walking Dead," cited "declines ...
One stock is dragging down the S&P 500's earnings growth
AOL· 3 days agoCompanies in the S&P 500 (^GSPC) have reported what's broadly been considered a solid Q1 earnings season for the index, with one key exception: drugmaker Bristol Myers Squibb (BMY). Last month ...
